Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response

NCT01827930 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

68

Enrollment

OTHER

Sponsor class

Stopped Difficulties of enrolment of Patient

Conditions

Leukemia, Myeloid, Chronic-Phase

Interventions

DRUG: Imatinib Mesylate 600 MG Oral Tablet
DRUG: Imatinib Mesylate 400 MG Oral Tablet
DRUG: Imatinib Mesylate

Sponsor

Institut Bergonié

Collaborators

[object Object]